A novel drug to treat osteoporosis comes with fewer side effects and may potentially be a new option for patients. The study was supported by National Institutes of Health and published in the Biophysical Journal.
"The technology can help make these calcitonin drugs safer and more effective," said research leader and professor, Elizabeth Topp. "Our approach will increase the therapeutic potential of human calcitonin, promising a more effective option to replace salmon calcitonin for osteoporosis and related disorders."
The findings show how a stabilized form of human calcitonin was used to create a prodrug.
"Many promising new peptide drugs tend to form fibrils," Topp said. "This technology provides a way to stabilize them in a reversible way so that the stabilizing modification comes off when the drug is given to the patient."
Learn more about osteoporosis:
Source: Science Daily
